Results 131 to 140 of about 2,540 (169)
Some of the next articles are maybe not open access.
Journal of Prescribing Practice
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #inclisiran
Julia Brandts, Kausik K. Ray
+4 more sources
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #inclisiran
Julia Brandts, Kausik K. Ray
+4 more sources
Inclisiran: A Review in Hypercholesterolemia
American Journal of Cardiovascular Drugs, 2023Inclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed
openaire +2 more sources
Inclisiran for the treatment of dyslipidemia
Expert Opinion on Investigational Drugs, 2018Dyslipidemia is one of the most important risk factors for cardiovascular disease. Insufficient reduction in LDL-C from existing therapies in patients at high risk of atherogenic cardiovascular disease is an unmet clinical need. Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hepatocytes.
Toshiyuki Nishikido, Kausik K. Ray
openaire +2 more sources
A Critical Review of the Efficacy and Safety of Inclisiran
American Journal of Cardiovascular Drugs, 2021The association between low-density cholesterol (LDL-C) and cardiovascular disease (CVD) is well-established, with an emphasis on lowering LDL-C levels to reduce cardiovascular events. Statin therapy has been the traditional treatment for LDL-C reduction, in addition to lifestyle modifications, but studies have shown that a substantial proportion of ...
Jennifer Hardy +6 more
openaire +2 more sources
Inclisiran in primary prevention: reality or fiction?
European Heart Journal, 2022This editorial refers to ‘Effect of inclisiran on lipids in primary prevention: the ORION-11 trial’, by K.K.
Gencer, Baris, Mach, François
openaire +2 more sources
No meaningful cardiovascular outcome data for inclisiran
Drug and Therapeutics Bulletin, 2023Abstract Overview of: Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023;44:129–38.
openaire +2 more sources
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
The American Journal of Cardiology, 2020Statin therapy is the gold standard for hypercholesterolemia. However, a significant number of patients cannot achieve their target low-density lipoprotein (LDL) levels despite a maximal dose of statin therapy, and some cannot tolerate statins at all. Approval of proprotein convertase subtilisin/kexin type 9 inhibitors has been revolutionary for those ...
Sajjad A. Khan +3 more
openaire +2 more sources
▼Inclisiran: more hope less hype
Drug and Therapeutics Bulletin, 2022Abstract
openaire +2 more sources
Journal of clinical lipidology, 2022
Despite the development of new therapies to lower cardiovascular disease (CVD) risk in recent decades, the trend of reductions in CVD mortality has reversed. New therapies are essential for the prevention of first and recurrent CVD. The importance of lowering low-density lipoprotein cholesterol (LDL-C) in the management and prevention of ...
Daniel, Soffer +2 more
openaire +1 more source
Despite the development of new therapies to lower cardiovascular disease (CVD) risk in recent decades, the trend of reductions in CVD mortality has reversed. New therapies are essential for the prevention of first and recurrent CVD. The importance of lowering low-density lipoprotein cholesterol (LDL-C) in the management and prevention of ...
Daniel, Soffer +2 more
openaire +1 more source
Canadian Journal of Health Technologies
CADTH recommends that Leqvio not be reimbursed by public drug plans as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) levels in adults who are on a maximally tolerated dose (MTD) of a statin, with or without other LDL-C–lowering therapies, and who have nonfamilial hypercholesterolemia ...
openaire +2 more sources
CADTH recommends that Leqvio not be reimbursed by public drug plans as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) levels in adults who are on a maximally tolerated dose (MTD) of a statin, with or without other LDL-C–lowering therapies, and who have nonfamilial hypercholesterolemia ...
openaire +2 more sources